
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 1 | 2 | 1 |
Stocks | 99 | 99 | 0 |
Bonds | 0 | 0 | 0 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 17 | 15 |
Price to Book | 2 | 2 |
Price to Sales | 2 | 1 |
Price to Cash Flow | 12 | 10 |
Dividend Yield | 2 | 3 |
5 Years Earnings Growth | 11 | 10 |
Name | Net % | Category Average |
---|---|---|
Consumer Cyclical | 24 | 12 |
Technology | 23 | 15 |
Healthcare | 20 | 8 |
Industrials | 13 | 18 |
Consumer Defensive | 10 | 7 |
Financial Services | 5 | 19 |
Communication Services | 3 | 6 |
Basic Materials | 3 | 6 |
Number of long holdings: 53
Number of short holdings: 2
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
SAP | DE0007164600 | 6.66 | 217.200 | -6.06% | |
Louis Vuitton | FR0000121014 | 6.17 | 493.60 | -6.87% | |
Santander | ES0113900J37 | 5.08 | 5.1005 | -7.08% | |
Hermes International | FR0000052292 | 4.68 | 2,105.00 | -7.39% | |
UCB | BE0003739530 | 4.46 | 141.05 | -6.37% | |
Dassault Systemes | FR0014003TT8 | 3.82 | 31.03 | -7.57% | |
EssilorLuxottica | FR0000121667 | 3.46 | 232.50 | -4.48% | |
Merck | DE0006599905 | 3.28 | 112.25 | -4.67% | |
Publicis Groupe | FR0000130577 | 2.99 | 75.12 | -7.14% | |
Biomerieux | FR0013280286 | 2.85 | 110.10 | -4.01% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Oddo Avenir Europe CR EUR | 1.14B | 6.30 | 0.46 | 4.79 | ||
Oddo Avenir Europe Ci EUR | 1.14B | 6.47 | 1.10 | 5.58 | ||
Oddo Avenir Europe CN EUR | 1.14B | 6.47 | 1.39 | 5.66 | ||
Oddo Avenir Europe DR EUR | 1.14B | 6.31 | 0.48 | 4.81 | ||
Oddo BHF Avenir CN EUR | 460.75M | 0.56 | -0.79 | - |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review